Margot N. et al.: Resistance Analysis of Long-Acting Lenacapavirin Highly Treatment-Experienced People with HIV after 26 Weeks of Treatment

Zurück zur Übersicht

27.-30.10.2021 / EACS

Studiensammlung zu HIV

Boopathy A. V. et al.: Immunogenicity and Prophylactic Efficacy of Arenavirus-Based SIV Vaccine in Macaques

12.-16.02.2022 / CROI

Cai Y. et al.: Immunological and Glycomic Correlates of Time to HIV Rebound in Viremic Controllers

12.-16.02.2022 / CROI

Cai Y. et al.: Viral and Biomarker Outcomes of an Engineered bNAb in ART-Suppressed Participants

12.-16.02.2022 / CROI

Cox S. et al.: Evaluation of HIV-1 Recency Assays Among Prospectively Observed HIV-1 Seroconversions

12.-16.02.2022 / CROI

Gupta S. K. et al.: Lenacapavir as part of a Combination Regimen in Treatment-Naïve People with HIV: Week 54 Results

12.-16.02.2022 / CROI

Margot N. et al.: Absence of Cross-Resistance to Lenacapavir in HIV Entry Inhibitor-Resistant Isolates

12.-16.02.2022 / CROI

Ogbuagu O. et al.: Long-Acting Lenacapavir in People With Multidrug-Resistant HIV-1: Week 52 Results

12.-16.02.2022 / CROI

Weber E. J. et al.: Pharmacokinetics of Lenacapavir in Participants With Severe Renal Impairment

12.-16.02.2022 / CROI

Wohl D. A. et al.: B/F/TAF Five-Year Outcomes in Treatment-Naïve Adults

12.-16.02.2022 / CROI

Zhang H. et al.: Evaluation of Potential Drug-Drug Interactions Between Islatravir and Lenacapavir

12.-16.02.2022 / CROI